Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM
Clinical trial NCT00648739 · TERMINATED
Trial details
- NCT number
- NCT00648739
- Sponsor
- Alexion Pharmaceuticals, Inc.
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2008-06-19
- Primary completion
- 2010-12-14
- Enrollment
- 26
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.